8-K: Galera Therapeutics Settles Lawsuit Over Phase 3 Trial Error, Receives $975,000

Galera Therapeutics has settled a lawsuit with its contract research organizations (CROs) related to a statistical error in a Phase 3 trial, receiving $975,000 and terminating contracts.

Summary

• Galera Therapeutics has settled a lawsuit with Alira Health Clinical, LLC and IQVIA Biotech, LLC.
• The lawsuit was related to a statistical error in the Phase 3 ROMAN trial of avasopasem.
• The error occurred in 2021 and involved the reduction of severe oral mucositis induced by radiotherapy.
• The settlement includes a payment of $975,000 to Galera.
• The contracts between Galera and the CROs have been terminated with no further obligations.
• Galera expects to file a Praecipe to Settle, Discontinue, and End the Litigation on or before August 8, 2024.

Sentiment

Score: 6

Explanation: The settlement is a positive step in resolving a legal issue, but the relatively small settlement amount and the underlying error in the clinical trial temper the overall positive sentiment.

Positives

• Galera received $975,000 as part of the settlement.
• The settlement resolves a legal dispute and removes uncertainty related to the Phase 3 ROMAN trial.
• The termination of contracts with the CROs simplifies future operations.

Risks

• The statistical error in the Phase 3 ROMAN trial highlights potential risks in clinical trial management.
• The settlement amount of $975,000 may not fully compensate for the impact of the error on the trial.

Future Outlook

The settlement resolves the legal dispute, allowing Galera to focus on future clinical development and operations.

Management Comments

• The document is signed by J. Mel Sorensen, M.D., President and Chief Executive Officer of Galera Therapeutics, Inc.

Industry Context

This settlement highlights the importance of accurate statistical analysis in clinical trials and the potential for disputes between pharmaceutical companies and their CROs. It is not uncommon for companies to have legal disputes with CROs, and this settlement is a resolution of such a dispute.

Comparison to Industry Standards

• Settlements in clinical trial disputes vary widely depending on the nature of the error and the impact on the trial. Some settlements can be in the millions of dollars, while others are much smaller.
• The $975,000 settlement is relatively small compared to some other settlements in the pharmaceutical industry, suggesting the error may not have had a catastrophic impact on the trial.
• Companies like ICON plc and PPD (now part of Thermo Fisher Scientific) are major CROs that often face similar issues, but the details of their settlements are not always public.

Legal Proceedings

• Galera Therapeutics settled a lawsuit with Alira Health Clinical, LLC and IQVIA Biotech, LLC related to a statistical error in the Phase 3 ROMAN trial.

Stakeholder Impact

• Shareholders may view the settlement as a positive step in resolving a legal issue.
• The settlement removes uncertainty related to the Phase 3 ROMAN trial.

Next Steps

• Galera will file a Praecipe to Settle, Discontinue, and End the Litigation on or before August 8, 2024.

Key Dates

Keywords

Galera Therapeutics, lawsuit, settlement, clinical trial, Phase 3 ROMAN trial, avasopasem, oral mucositis, contract research organization, CRO, Alira Health Clinical, IQVIA Biotech